Brokerages Anticipate Voyager Therapeutics, Inc. (VYGR) Will Post Earnings of -$0.69 Per Share
Equities research analysts expect that Voyager Therapeutics, Inc. (NASDAQ:VYGR) will announce earnings per share (EPS) of ($0.69) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Voyager Therapeutics’ earnings, with estimates ranging from ($0.78) to ($0.48). Voyager Therapeutics posted earnings of ($0.35) per share during the same quarter last year, which suggests a negative year over year growth rate of 97.1%. The firm is expected to announce its next earnings results on Thursday, November 9th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($2.82) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($2.33). For the next financial year, analysts expect that the business will report earnings of ($2.59) per share, with EPS estimates ranging from ($3.29) to ($1.99). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million.
Several equities analysts have issued reports on VYGR shares. Stifel Nicolaus restated a “buy” rating and issued a $33.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, June 27th. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital restated a “hold” rating on shares of Voyager Therapeutics in a research report on Sunday, September 10th. Finally, Evercore ISI started coverage on shares of Voyager Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $12.00 price target for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Voyager Therapeutics presently has an average rating of “Hold” and a consensus target price of $24.83.
In other news, insider Bernard Ravina sold 16,470 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders sold 27,450 shares of company stock worth $321,769. Insiders own 8.00% of the company’s stock.
Several large investors have recently bought and sold shares of VYGR. Teachers Advisors LLC boosted its stake in shares of Voyager Therapeutics by 9.8% in the 4th quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock valued at $262,000 after purchasing an additional 1,847 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Voyager Therapeutics by 114.4% in the 1st quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock valued at $1,107,000 after purchasing an additional 44,599 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Voyager Therapeutics by 15.6% in the 1st quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock valued at $582,000 after purchasing an additional 5,952 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after purchasing an additional 19,450 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Voyager Therapeutics by 3.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock valued at $383,000 after purchasing an additional 1,026 shares during the last quarter. 40.70% of the stock is currently owned by institutional investors.
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down 8.00% during trading on Wednesday, reaching $20.25. 305,166 shares of the company’s stock were exchanged. The stock’s market cap is $544.79 million. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $22.95. The stock’s 50 day moving average price is $13.75 and its 200-day moving average price is $10.93.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at http://www.mareainformativa.com/brokerages-anticipate-voyager-therapeutics-inc-vygr-will-post-earnings-of-0-69-per-share/116137/.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.